Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19

Trial ID or NCT#

NCT04805671

Status

not recruiting iconNOT RECRUITING

Purpose

This placebo controlled study is intended to generate safety and efficacy data in order to provide a treatment option for COVID-19 in patients with a high risk of disease progression based on age or co-morbid medical conditions.

Official Title

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants With Mild or Moderate COVID-19 (STAMP)

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Peter Schmidt
Peter Schmidt
Anesthesiologist, Pain management specialist
Clinical Assistant Professor, Anesthesiology, Perioperative and Pain Medicine

View on ClinicalTrials.gov